Effect of Methyl-Sulphonyl-Methane on Osteoarthritis and Cartilage

The Effect of Methyl-Sulphonyl-Methane on Osteoarthritis and Joint Cartilage Associated With the Degeneration of the Chondrocyte

Status

UNKNOWN

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01836757

Acronym

msm

Enrollment

100

Registered

2013-04-22

Start date

2012-09-30

Completion date

2013-10-31

Last updated

2013-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis

Keywords

osteoarthritis, CAM treatments, MSM

Brief summary

To delineate the effect of MSM on osteoarthritis

Detailed description

Objective: To delineate the effect of MSM on osteoarthritis of large joints. Design: Randomized, double-blind, placebo-controlled trial including an intervention and a placebo group. One hundred men and women, with hip and/or knee OA to be divided in 2 groups. Intervention is either MSM 3 gr twice a day for 26 weeks (6 gr/day total) for one group and placebo for the other. Outcomes measured are the Western Ontario and McMaster University Osteoarthritis Index visual analogue scale (WOMAC), patient and physician assessments and SF-36 (overall health-related quality of life).

Interventions

DRUGMethylSulfonylMethane (MSM)

Intervention is MSM 3 gr twice a day for 26 weeks (6 gr/day total)

DRUGPlacebo

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SUPPORTIVE_CARE

Masking

DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

40 Years to No maximum

Healthy volunteers

Inclusion criteria

* Knee and hip OA * men and women \>45 years of age

Exclusion criteria

* any other type of arthritis * chronic pain syndrome * arthroscopic surgery in the past 8 months * intra-articular corticosteroidsin the past 8 months * hyaluronic acid injections in the past 8 months * narcotic pain killers use * renal or hepatic disease * body mass index (BMI) \>45 kg/m2 * cancer

Design outcomes

Primary

Measure	Time frame	Description
Number of participants with improved Mobility	26 weeks	Randomized, double-blind, placebo-controlled trial including an intervention and a placebo group. One hundred men and women, with hip and/or knee OA were divided in 2 groups. Intervention was either MSM 3 gr twice a day for 26 weeks (6 gr/day total) for one group and placebo for the other. Outcomes measured were the Western Ontario and McMaster University Osteoarthritis Index visual analogue scale (WOMAC)

Secondary

Measure	Time frame	Description
Pain Scores on the Visual Analog Scale	26 weeks	On the same two groups (MSM and Placebo)we measured the improvement of quality of life through pain relief as measured by use of SF-36 (overall health-related quality of life)

Countries

Greece

Contacts

Primary ContactThomas Pagonis, MD, PhD

iatros1@yahoo.com00306980488686

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026